MedTrace Logo

A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets

NCT01405131 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2018-10-30

No results posted yet for this study

Summary

A study to determine whether a new formulation of methylprednisolone suspension is bioequivalent to methylprednisolone tablets.

Conditions

  • Therapeutic Equivalency

Interventions

DRUG

methylprednisolone

constituted powder for oral suspension 4 mg/mL single dose at 32 mg

DRUG

methylprednisolone

tablets 32 mg single dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-01
Primary Completion
2012-02-20
Completion
2012-02-20

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01405131 on ClinicalTrials.gov